22nd Century ROE 2011-2023 | XXII
Current and historical return on equity (ROE) values for 22nd Century (XXII) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| 22nd Century ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-09-30 |
$-0.14B |
$0.01B |
-209.09% |
| 2023-06-30 |
$-0.08B |
$0.07B |
-84.10% |
| 2023-03-31 |
$-0.07B |
$0.08B |
-68.51% |
| 2022-12-31 |
$-0.06B |
$0.10B |
-63.10% |
| 2022-09-30 |
$-0.05B |
$0.12B |
-54.65% |
| 2022-06-30 |
$-0.04B |
$0.10B |
-56.95% |
| 2022-03-31 |
$-0.04B |
$0.06B |
-49.66% |
| 2021-12-31 |
$-0.03B |
$0.07B |
-45.07% |
| 2021-09-30 |
$-0.02B |
$0.08B |
-36.64% |
| 2021-06-30 |
$-0.02B |
$0.09B |
-32.62% |
| 2021-03-31 |
$-0.02B |
$0.05B |
-40.00% |
| 2020-12-31 |
$-0.02B |
$0.04B |
-36.89% |
| 2020-09-30 |
$-0.02B |
$0.05B |
-33.93% |
| 2020-06-30 |
$-0.03B |
$0.05B |
-43.67% |
| 2020-03-31 |
$-0.03B |
$0.06B |
-47.26% |
| 2019-12-31 |
$-0.03B |
$0.06B |
-41.77% |
| 2019-09-30 |
$-0.03B |
$0.06B |
-44.96% |
| 2019-06-30 |
$-0.01B |
$0.06B |
-18.44% |
| 2019-03-31 |
$-0.01B |
$0.07B |
-16.38% |
| 2018-12-31 |
$-0.01B |
$0.07B |
-11.96% |
| 2018-09-30 |
$-0.00B |
$0.08B |
-5.25% |
| 2018-06-30 |
$-0.01B |
$0.07B |
-20.47% |
| 2018-03-31 |
$-0.01B |
$0.08B |
-17.48% |
| 2017-12-31 |
$-0.01B |
$0.08B |
-34.67% |
| 2017-09-30 |
$-0.01B |
$0.03B |
-48.48% |
| 2017-06-30 |
$-0.01B |
$0.03B |
-55.17% |
| 2017-03-31 |
$-0.01B |
$0.02B |
-63.16% |
| 2016-12-31 |
$-0.01B |
$0.02B |
-67.61% |
| 2016-09-30 |
$-0.01B |
$0.02B |
-81.36% |
| 2016-06-30 |
$-0.01B |
$0.01B |
-84.21% |
| 2016-03-31 |
$-0.01B |
$0.02B |
-66.67% |
| 2015-12-31 |
$-0.01B |
$0.01B |
-80.00% |
| 2015-09-30 |
$-0.01B |
$0.01B |
-96.55% |
| 2015-06-30 |
$-0.01B |
$0.02B |
-87.50% |
| 2015-03-31 |
$-0.02B |
$0.01B |
-107.14% |
| 2014-12-31 |
$-0.02B |
$0.02B |
-118.52% |
| 2014-09-30 |
$-0.02B |
$0.02B |
-153.19% |
| 2014-06-30 |
$-0.03B |
$0.01B |
-1200.00% |
| 2014-03-31 |
$-0.03B |
$0.01B |
1866.67% |
| 2013-12-31 |
$-0.03B |
$0.01B |
433.33% |
| 2013-09-30 |
$-0.02B |
$-0.02B |
231.58% |
| 2013-06-30 |
$-0.01B |
$-0.01B |
121.74% |
| 2013-03-31 |
$-0.01B |
$-0.01B |
155.56% |
| 2012-12-31 |
$-0.01B |
$-0.01B |
184.62% |
| 2012-09-30 |
$-0.00B |
$-0.00B |
50.00% |
| 2012-06-30 |
$-0.00B |
$-0.00B |
44.44% |
| 2012-03-31 |
$-0.00B |
$-0.00B |
80.00% |
| 2011-12-31 |
$-0.00B |
$-0.00B |
44.44% |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.006B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
